ePRO Reporting Methods for Multiple Myeloma
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests two methods for patients with multiple myeloma (a type of blood cancer) to report symptoms: a text messaging system called TXT-Chatbot and a patient portal like MyChart. The researchers aim to determine which method patients prefer and find more engaging for sharing their feelings. Tracking symptoms is crucial because it helps doctors make better treatment decisions. Patients diagnosed with multiple myeloma who can use text or internet and speak English are suitable for this study. If successful, the trial may enhance patient communication with healthcare teams, potentially leading to better care. As an unphased trial, it offers patients a chance to contribute to improving symptom tracking and communication methods, potentially enhancing their own care experience.
Do I need to stop my current medications for this trial?
The trial protocol does not specify whether you need to stop taking your current medications. It seems focused on how you report symptoms rather than changing your treatment.
What prior data suggests that these ePRO reporting methods are safe for multiple myeloma patients?
Research shows that both the TXT-Chatbot and MyChart/Patient Portal systems are safe for patients with multiple myeloma. Previous studies using similar electronic tools for tracking symptoms have not identified any major safety issues.
The TXT-Chatbot allows patients to report symptoms via text messages. This method has been tested in other contexts without significant problems. While research on using text messaging for health monitoring continues, it is generally considered safe.
MyChart/Patient Portal is a well-known system. Studies have shown it improves health outcomes for patients with multiple myeloma. It is widely used and regarded as safe.
Overall, both systems are well-received by patients. No reports have linked harmful effects directly to these platforms. They offer a convenient way for patients to share their health status, aiding doctors in making informed decisions.12345Why are researchers excited about this trial?
Researchers are excited about this trial because it explores new ways to help multiple myeloma patients manage their symptoms and treatment progress more effectively using digital tools. Unlike traditional methods that might rely on in-person visits or phone calls, this trial investigates the use of a TXT-Chatbot and MyChart/Patient Portal to facilitate patient communication and data collection through regular surveys. These digital interventions aim to provide a more convenient and consistent way for patients to report their health status, potentially leading to better personalized care and improved outcomes.
What evidence suggests that these reporting methods are effective for multiple myeloma?
This trial will compare two electronic reporting methods for multiple myeloma: TXT-Chatbot and MyChart/Patient Portal. Research has shown that using text messages and patient portals to report symptoms can enhance the quality of life for people with multiple myeloma. Studies indicate that electronic tools for reporting symptoms (ePROs) help patients manage their symptoms more effectively. Participants in the TXT-Chatbot group gained more knowledge about their condition, boosting their confidence in managing their disease. Meanwhile, MyChart, a patient portal, has been linked to better health outcomes, particularly for those in vulnerable communities. Overall, both methods show promise in helping patients track symptoms and improve their health.12678
Are You a Good Fit for This Trial?
This trial is for adults with Multiple Myeloma who can use text messaging or have internet access, understand English, and are post-autologous stem cell transplant. It excludes those under 18 or with documented cognitive impairment.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive notifications and complete surveys through either TXT-Chatbot or MyChart/Patient Portal every two weeks for 6 months
Follow-up
Participants are monitored for satisfaction and adherence to the ePRO system after the intervention
What Are the Treatments Tested in This Trial?
Interventions
- Behavioral Intervention
Find a Clinic Near You
Who Is Running the Clinical Trial?
Thomas Jefferson University
Lead Sponsor